Literature DB >> 10321477

Compensatory mechanism of motor defect in SOD1 transgenic mice by overactivation of striatal cholinergic neurons.

M Azzouz1, W Krezel, P Dollé, C Vodouhe, J M Warter, P Poindron, J Borg.   

Abstract

Expression of a mutant superoxide dismutase 1 (SOD1) gene in transgenic mice induces a gradual degeneration of cholinergic motor neurons in the spinal cord, causing progressive muscle weakness and hindlimb paralysis. Transgenic mice over-expressing the human SOD1 gene containing a Gly-->Ala substitution at position 93 (G93A) were employed to explore the effects of the SOD1 mutation on choline acetyltransferase (ChAT) expression in the striatum, and in the lumbar and cervical spinal cord. These mice showed a progressive loss of their spinal cord motor neurons, and at 130 days of age showed an up-regulation of ChAT mRNA expression in the striatum. On the other hand, ChAT mRNA decreased in cervical and lumbar motor neurons. These findings suggest that cholinergic interneurons in striatum in SOD1 transgenic mice are over-activated in an attempt to compensate for the death of spinal motor neurons.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10321477     DOI: 10.1097/00001756-199904060-00022

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  3 in total

Review 1.  Genotype to phenotype: challenges and opportunities.

Authors:  D P Holschneider; J C Shih
Journal:  Int J Dev Neurosci       Date:  2000-10       Impact factor: 2.457

2.  Pre-symptomatic detection of chronic motor deficits and genotype prediction in congenic B6.SOD1(G93A) ALS mouse model.

Authors:  C R Hayworth; F Gonzalez-Lima
Journal:  Neuroscience       Date:  2009-08-20       Impact factor: 3.590

3.  eGFP expression under UCHL1 promoter genetically labels corticospinal motor neurons and a subpopulation of degeneration-resistant spinal motor neurons in an ALS mouse model.

Authors:  Marina V Yasvoina; Baris Genç; Javier H Jara; Patrick L Sheets; Katharina A Quinlan; Ana Milosevic; Gordon M G Shepherd; C J Heckman; P Hande Özdinler
Journal:  J Neurosci       Date:  2013-05-01       Impact factor: 6.167

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.